Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles Locke

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Journal of Biopharmaceutical Statistics|June 22, 2013
Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studiesZhiwu Yan, Balakrishna Hosmane, Charles Locke
Journal of Biopharmaceutical Statistics|June 22, 2013
The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studiesBalakrishna Hosmane, Charles Locke, Yi-Lin Chiu
Journal of Biopharmaceutical Statistics|April 2, 2010
Sample size and power estimation in "thorough" QT/QTc studies with parallel group designBalakrishna Hosmane, Charles Locke, Yi-Lin Chiu
Journal of Biopharmaceutical Statistics|April 2, 2010
Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studiesBalakrishna Hosmane, Charles Locke, Yi-Lin Chiu
Pain Medicine (Malden, Mass.)|January 28, 2016
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy AdultsMark Wallace, Rachel Duan, Wei Liu, et al.
Clinical Pharmacology in Drug Development|May 21, 2016
A Phase 1 Study to Evaluate the Bioavailability and Food Effect of 2 Solid-Dispersion Formulations of the TRPV1 Antagonist ABT-102, Relative to the Oral Solution Formulation, in Healthy Human VolunteersAhmed A Othman, Howard Cheskin, Charles Locke, et al.
Journal of Parkinson'S Disease|February 18, 2017
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-CarbidopaAhmed A Othman, Matthew Rosebraugh, Krai Chatamra, et al.
Psychopharmacology|September 27, 2015
Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436David A Katz, Wei Liu, Charles Locke, et al.
Brain and Behavior|March 16, 2017
Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trialDavid A Katz, Charles Locke, Nicholas Greco, et al.
British Journal of Clinical Pharmacology|November 13, 2013
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteersAhmed A Othman, George Haig, Hana Florian, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Journal of Biopharmaceutical Statistics|June 22, 2013
Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studiesZhiwu Yan, Balakrishna Hosmane, Charles Locke
Journal of Biopharmaceutical Statistics|June 22, 2013
The joint modeling of drug and positive control effects to estimate sample size and power in crossover "thorough" QT/QTc studiesBalakrishna Hosmane, Charles Locke, Yi-Lin Chiu
Journal of Biopharmaceutical Statistics|April 2, 2010
Sample size and power estimation in "thorough" QT/QTc studies with parallel group designBalakrishna Hosmane, Charles Locke, Yi-Lin Chiu
Journal of Biopharmaceutical Statistics|April 2, 2010
Exposure-response modeling approach for assessing QT effect in "thorough" QT/QTc studiesBalakrishna Hosmane, Charles Locke, Yi-Lin Chiu
Pain Medicine (Malden, Mass.)|January 28, 2016
A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of the T-Type Calcium Channel Blocker ABT-639 in an Intradermal Capsaicin Experimental Pain Model in Healthy AdultsMark Wallace, Rachel Duan, Wei Liu, et al.
Clinical Pharmacology in Drug Development|May 21, 2016
A Phase 1 Study to Evaluate the Bioavailability and Food Effect of 2 Solid-Dispersion Formulations of the TRPV1 Antagonist ABT-102, Relative to the Oral Solution Formulation, in Healthy Human VolunteersAhmed A Othman, Howard Cheskin, Charles Locke, et al.
Journal of Parkinson'S Disease|February 18, 2017
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-CarbidopaAhmed A Othman, Matthew Rosebraugh, Krai Chatamra, et al.
Psychopharmacology|September 27, 2015
Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436David A Katz, Wei Liu, Charles Locke, et al.
Brain and Behavior|March 16, 2017
Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trialDavid A Katz, Charles Locke, Nicholas Greco, et al.
British Journal of Clinical Pharmacology|November 13, 2013
The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteersAhmed A Othman, George Haig, Hana Florian, et al.
Pageof 3